Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

DDMORE

Financiado

Drug Disease Model Resources

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quant... ver más

31/08/2016

Pfizer RD UK Limit...

23M€

Presupuesto del proyecto: 23M€

Líder del proyecto

Pfizer RD UK Limited No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 23 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2016-08-31

0% 100%

23 Participantes

Pfizer RD UK Limited

Lider

UPNA

N.D. | Participante

INRIA

N.D. | Participante

ULEI

N.D. | Participante

Proyectos interesantes

SAF2016-78756-P MODELOS IN VITRO DE EVALUACION BIOFARMACEUTICA: BARRERAS BIO... 85K€ Cerrado

PRE2021-100416 MEDICINA INTERCEPTIVA, DESCUBRIMIENTO DE DIANAS Y REUTILIZAC... 101K€ Cerrado

ORBITO Oral biopharmaceutics tools 25M€ Cerrado

SAF2009-12768 MODELIZACION Y SIMULACION PARA DISEÑO Y DESARROLLO DE NUEVOS... 109K€ Cerrado

PTQ2018-010262 Investigación de modelos computacionales para la determinaci... 62K€ Cerrado

ERAMET Ecosystem for rapid adoption of modelling and simulation MET... 4M€ Cerrado

Últimas noticias

02-12-2024: AGENCIA-VALENCIANA-D... En las últimas 48 horas el Organismo AGENCIA VALENCIANA D... ha otorgado 1 concesiones

02-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 4 concesiones

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

Duración del proyecto: 65 meses Fecha Inicio: 2011-03-01
Fecha Fin: 2016-08-31

Líder del proyecto

Pfizer RD UK Limited

TRL 4-5

Presupuesto del proyecto 23M€

Descripción del proyecto Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capable of describing and predicting the behaviour of studied systems to address the questions researchers, regulators, and public health care bodies face when bringing drugs to patients.The full adoption of MBDD is frustrated by a lack of common tools, languages and ontologies for M&S, which often leads to inefficient reuse of data and duplication of effort by academic, industrial and regulatory stakeholders.The Drug Disease Model Resources (DDMoRe) consortium’s strategy will have standards as its core: a newly developed common definition language for data, models and workflows, along with an ontology based standard for storage and transfer of models and associated metadata.A drug and disease model library will be developed as a public resource. Its flexibility and power will be showcased by the addition of proof of concept” drug and disease models from key therapeutic areas such as diabetes and oncology.An open-source interoperability framework will be the backbone for the integration of M&S applications into seamless, standardized but flexible workflows. Initially, currently-used tools (e.g. NONMEM, WinBUGS, Matlab, R) will be integrated into the framework. From the outset resources will also be dedicated to new application development which will be steered by identified gaps in the M&S software ecosystem.The DDMoRe project’s standards and tools – intended as the gold standard for future collaborative drug and disease M&S - will be supported by comprehensive training and will be made publicly accessible.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores